Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Progression-free survival was longer with nivolumab plus ipilimumab than with chemotherapy among patients who had not previously received systemic treatment for MSI-H or dMMR metastatic colorectal cancer. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 8HW ClinicalTrials.gov number, NCT04008030.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2024-11-27
DOI
https://doi.org/10.1056/nejmoa2402141
Citations
170
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
48.03

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Laëtitia Dahan, Eray Goekkurt, Ming Lei, Tian Chen et al.
170 citations
New England Journal of Medicine
Colorectal Cancer Treatments and Studies
48.03
article

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Laëtitia Dahan, Eray Goekkurt, Ming Lei, Tian Chen, Michael Schenker, Jaafar Bennouna, María Luisa Limón, Guillermo Méndez, Lars Henrik Jensen, Elvis Cela, Heinz‐Josef Lenz, Timuçin Çil, Rocio García‐Carbonero, Giampaolo Tortora, Sara Lonardi, Myriam Chalabi, Christelle de la Fouchardière, Takayuki Yoshino, Maria Ignez Braghiroli, Thierry André, Eric Van Cutsem, Jin Li, Matthew Dixon, Rohit Joshi, Elena Élez, Sandzhar Abdullaev, José Luis Manzano Mozo
article en
170 citations

Abstract

Progression-free survival was longer with nivolumab plus ipilimumab than with chemotherapy among patients who had not previously received systemic treatment for MSI-H or dMMR metastatic colorectal cancer. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 8HW ClinicalTrials.gov number, NCT04008030.).

New England Journal of MedicineVol. 391(21)
Sorbonne Université (FR), Hôpital Saint-Antoine (FR)
Bristol-Myers Squibb
Good health and well-being
Openalex Percentile: Top 0%
Colorectal Cancer Treatments and Studies
48.03
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.